ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – What’s Next?

ProPhase Labs, Inc. (NASDAQ:PRPH) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.24 and traded as low as $0.1035. ProPhase Labs shares last traded at $0.1198, with a volume of 56,021 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised ProPhase Labs to a “hold” rating in a research report on Saturday, December 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ProPhase Labs currently has an average rating of “Sell”.

ProPhase Labs Stock Down 0.2%

The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $721,435.60, a P/E ratio of -0.03 and a beta of -0.33. The stock’s 50 day simple moving average is $0.12 and its 200 day simple moving average is $1.24.

Institutional Investors Weigh In On ProPhase Labs

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in ProPhase Labs during the 2nd quarter valued at $40,000. Apollon Wealth Management LLC bought a new position in shares of ProPhase Labs in the third quarter worth $84,000. Accretive Wealth Partners LLC acquired a new position in shares of ProPhase Labs during the third quarter valued at $114,000. Finally, Susquehanna International Group LLP increased its holdings in shares of ProPhase Labs by 290.1% during the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares during the period. 9.45% of the stock is currently owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.